2026· American journal of clinical and experimental urology· Vol 14 3, pp.
64-85
· 2 citations
Medicine
TL;DR
Recent discoveries from single-cell and spatial analyses are summarized, their implications for biomarker development and treatment stratification are discussed, and ongoing technical challenges are outlined, including standardization, reproducibility, and clinical scalability.
Abstract
Prostate cancer is a heterogeneous disease shaped by evolving cellular states within a spatially organized tumor ecosystem. Advances in single-cell RNA-sequencing, single-nucleus sequencing, and spatial transcriptomics have facilitated high-resolution dissection of epithelial lineage hierarchies, tumor-associated luminal states, and microenvironmental remodeling. These approaches have revealed that progression from androgen receptor-dependent adenocarcinoma to castration-resistant prostate cancer and the development of neuroendocrine phenotypes reflect lineage plasticity and epigenetic reprogramming rather than simple linear genetic progression. Single-cell studies have indicated that immunosuppressive niches, cancer-associated fibroblast heterogeneity, endothelial activation, and metabolic adaptation collectively contribute to therapeutic resistance. The integration of multi-omics data with spatial context has begun to redefine prostate cancer taxonomy based on cellular state composition and ecosystem architecture. In this review, we summarize recent discoveries from single-cell and spatial analyses, discuss their implications for biomarker development and treatment stratification, and outline ongoing technical challenges, including standardization, reproducibility, and clinical scalability. Overall, this review provides valuable insights for the development of a state-informed framework to understand prostate cancer progression and guide precision oncology strategies.
This review synthesizes single-cell and spatial omics evidence for metabolic-immune ecosystems in prostate cancer, emphasizing the transition from androgen dependence to castration resistance, lineage plasticity, metastatic niche adaptation, and therapy resistance.
How single-cell and spatial omics are reshaping the understanding of metabolic reprogramming and tumor–immune ecosystems in NSCLC is discussed, and how these findings may inform biomarker discovery, patient stratification, resistance monitoring, and rational combination therapy are discussed.
Zhenzhen Lian, Xu-Jing Wu, Yangyang Zhou et al.· Frontiers in Immunology· 0 citations
It is found that SFRP2-expressing fibroblasts accumulated in aged skin and were also enriched in tumor-associated stroma, suggesting that this pre-existing fibroblast state may become incorporated into and potentially support the tumor microenvironment during skin cancer development.
D. Pan, Haibin Wu· Frontiers in Medicine· 0 citations
This review synthesizes key advances in understanding tumor heterogeneity: from its cellular origins and molecular mechanisms to its multidimensional manifestation in the tumor microenvironment and from metastatic heterogeneity to the fundamental causes of treatment resistance.
Jianhong Zhang, Heng Li, S. Ru et al.· Signal Transduction and Targ...· 1 citation
It is suggested that integrated single-cell and spatial transcriptomics offers transformative potential to advance precision oncology and improve outcomes for patients with pancreatic cancer.
Mengting Luo, Feng Shen, Wanli Xu et al.· Cancer Biology & Therapy· 0 citations
The uncovered molecular signatures offered mechanistic clues linking EMT, hormone resistance, and local immune status during lesion evolution and preliminary molecular evidence to support pathological stratification and targeted precision therapeutic strategies for PCa was provided.